[1]
Asyifah, M.R.; Lu, K.; Ting, H.L.; Zhang, D. Hidden potential of tropical fruit waste components as a useful source of remedy for obesity. J. Agric. Food Chem., 2014, 62(16), 3505-3516.
[2]
Christopher, R.; Morgan, M.; Ferry, J.; Rege, B.; Tang, Y.; Kristensen, A.; Shanahan, W. Single and multiple-dose pharmacokinetics of a lorcaserin extended-release tablet. Clin. Ther., 2016, 38(10), 2227-2238.
[3]
Kang, J.G.; Park, C. Anti-Obesity drugs: A review about their effects and safety. Diabetes Metab. J., 2012, 36(1), 13-25.
[4]
Dixon, J.B. Advances in managing obesity. Nat. Publ. Gr.,, 2016, 2015-2016.
[5]
Manning, S.; Pucci, A.; Finer, N. Pharmacotherapy for obesity: Novel agents and paradigms. Ther. Adv. Chronic Dis., 2014, 5(3), 135-148.
[6]
Xia, Y.; Kelton, C.M.L.; Guo, J.J.; Bian, B.; Heaton, P.C. Treatment of obesity: Pharmacotherapy trends in the united states from 1999 to 2010. Obesity , 2015, 23, 1721-1728.
[7]
Klonoff, D.C.; Greenway, F. Drugs in the pipeline for the obesity market. J. Diabetes Sci. Technol., 2008, 2, 913-918.
[8]
Hendricks, E.J. Off-Label drugs for weight management. Diabetes Metabol. Syndrome Obesity: Targets Therapy, 2017, 10, 223-234.
[9]
Aronne, L.; Shanahan, W.; Fain, R.; Glicklich, A.; Soliman, W.; Smith, S. Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials. Postgrad. Med., 2014, 126, 7-18.
[10]
Gurevich-panigrahi, T.; Panigrahi, S.; Wiechec, E.; Los, M. Obesity: Pathophysiology and clinical management. Curr. Med. Chem., 2009, 16(4), 506-521.
[11]
Adan, R.A.H. Mechanisms Underlying current and future anti-obesity drugs. Trends Neurosci., 2013, 36, 133-140.
[12]
Rodríguez, J.E. Past, present and future pharmacological therapy in obesity stimulants fat blockers antidepressants pharmacology treatment. Prim. Care Mar., , 2016, 43(1), 61-67.
[13]
Lois, K.; Kumar, S. Pharmacotherapy of Obesity. Endocrinol. Nutr., 2009, 56(4), 223-235.
[14]
Rodgers, R.J.; Tschop, M.H.; Wilding, J.P.H. Anti-Obesity drugs: Past, present and future. Dis. Model. Mech., 2012, 5, 621-626.
[15]
Hatahet, M.A.; Dhurandhar, N.V. Antiobesity drugs: Current and future issues. Curr. Diab. Rep., 2002, 2, 409-415.
[16]
Colman, E. Dinitrophenol and obesity: An early twentieth-century regulatory dilemma. Regul. Toxicol. Pharmacol., 2007, 48, 115-117.
[17]
Haslam, D. Weight Management In Obesity – Past and present. Int. J. Clin. Pract., 2016, 70(3), 206-217.
[18]
Hofbauer, E.; Karl, G.; Data, O.B. Pharmacotherapy of Obesity; CRC Press, 2004, Vol. 5, .
[19]
Hopkins, C.R. ACS chemical neuroscience molecule spotlight on lorcaserin. ACS Chem. Neurosci., 2010, 17(11), 718-719.
[20]
Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med., 2010, 363.
[21]
Zhao, H.; Guo, Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov. Today, 2009, 14, 516-522.
[22]
Redman, L.M.; Ravussin, E. Lorcaserin for the treatment of obesity. Drugs Today , 2010, 46, 901-910.
[23]
Hoy, S.M. Lorcaserin: A review of its use in chronic weight management. Drugs, 2013, 73, 463-473.
[24]
Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) study group.Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med., 2010, 363, 245-256.
[25]
Harmonization, R.; Programme, M.; Issues, E. WHO Drug Information., 2012, 26.
[26]
Qihua Zhu; Wang, J.; Bian, X.; Zhang, L.; Wei, P.; Xu, Y. Novel synthesis of anti-obesity drug lorcaserin hydrochloride. Org. Process Res. Dev., 2015, 19, 1263-1267.
[27]
Cluzeau, J.; Stavber, G. Development and optimization of a new synthetic process for lorcaserin. Bioorg. Med. Chem., 2018, 26, 977-983.
[28]
Thomsen, W.J.; Grottick, A.J.; Menzaghi, F.; Reyes-saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; Al-shamma, H.; Smith, B.; Chalmers, D.; Behan, D. Lorcaserin, a novel selective human 5-hydroxytryptamine 2c agonist: In Vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther., 2008, 325, 577-587.
[29]
Bajrai, A.A.; Ezzeldin, E.; Al-rashood, K.A.; Raish, M.; Iqbal, M. Article A validated UPLC – MS-MS assay for the rapid determination of lorcaserin in plasma and brain tissue samples. J. Anal. Toxicol., 2016, 40(2), 133-139.
[30]
Wani, D.V.; Rane, V.P.; Mokale, S.N. Liquid chromatographic separation and thermodynamic investigation of lorcaserin hydrochloride enantiomers on immobilized amylose-based chiral stationary phase. Chirality, 2018, 30, 284-292.
[31]
Rajput, S.J.; Sathe, M.A.; Patel, S.D. Development and validation of a hplc-based bioanalytical method for lorcaserin using solid phase extraction and application to a pharmacokinetic study in rats. Indian J. Pharm. Sci., 2018, 80, 235-241.
[32]
Hachem, R.; Malet-Martino, M.; Gilard, V. First identification and quantification of lorcaserin in an herbal slimming dietary supplement. J. Pharm. Biomed. Anal., 2014, 98, 94-99.
[33]
Bays, H.E. Lorcaserin: Drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev. Cardiovasc. Ther., 2011, 9, 265-277.
[34]
Fda Briefing Document Nda 200677 Pasireotide Injection: 600 Mcg, 900 Mcg Sponsor: Novartis Pharmaceuticals Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2012.
[35]
Colman, E. Department of health and human services public, health service food and drug administration center for drug evaluation and research., 2010, 1-11.
[36]
Smith, S.R.; Garvey, W.T.; Greenway, F.L.; Zhou, S.; Fain, R.; Pilson, R.; Fujioka, K.; Aronne, L.J. Coadministration of lorcaserin and phentermine for weight management: A 12-Week, randomized, pilot safety study. Obesity (Silver Spring), 2017, 25, 857-865.
[37]
For, A.; Disclosure, P.; Redaction, W. Lorcaserin hydrochloride briefing document for FDA advisory committee meeting., 2012.
[38]
Hurren, K.M.; Berlie, H.D. Lorcaserin: An Investigational Serotonin 2C Agonist for Weight Loss. Am. J. Heal. Pharm.,, 2011. 68, 2029 LP-2037.
[39]
Shukla, A.P.; Kumar, R.B.; Aronne, L.J. Lorcaserin Hcl for the Treatment of Obesity. Expert Opin. Pharmacother., 2015, 16, 2531-2538.
[40]
Sadeque, A.J.M.; Usmani, K.A.; Palamar, S.; Cerny, M.A.; Chen, W.G. Identification of Human UDP-Glucuronosyltransferases Involved in N-Carbamoyl Glucuronidation of Lorcaserin. Drug Metab. Dispos., 2012, 40, 772-778.
[41]
Sadeque, A.J.M.; Palamar, S.; Usmani, K.A.; Chen, C.; Cerny, M.A.; Chen, W.G. Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation. Drug Metab. Dispos., 2016, 44, 570-575.
[42]
Berlie, H.D.; Hurren, K.M. Evaluation of Lorcaserin for the Treatment of Obesity. Expert Opin. Drug Metab. Toxicol., 2013, 9(8), 1053-1059.
21
1